A more complex molecular landscape of HER2-low breast cancer might exist, and novel sensitive assays that can further distinguish HER2-levels could be investigated, thus offering new therapeutic targets for breast cancer treatment. The gene discussed is ERBB2; the disease is breast carcinoma.